Boomi World 2025: Accelerating What’s Next in AI, Integration, and the Connected Enterprise
24.4.2025 15:00:00 CEST | Business Wire | Press release
Boomi’s flagship event brings together global innovators shaping the future of AI, integration, and automation
Boomi™, the intelligent integration and automation leader, is excited to announce that Boomi World 2025 will be held May 12-15, 2025, in Dallas, Texas. This premier event will showcase the latest advancements in AI-driven integration and automation, bringing together industry leaders, innovative thinkers, and Boomi customers and partners to explore how these technologies are reshaping the future. Attendees will gain valuable insights on how to break down silos, streamline operations, and make informed, data-driven decisions through a series of keynote sessions, breakout discussions, and hands-on training opportunities.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250424969941/en/
Boomi World 2025: Accelerating What’s Next in AI, Integration, and the Connected Enterprise
Emceed by technology industry veteran and correspondent Lisa Martin, Boomi World 2025 will feature esteemed speakers, including:
- Tara Davis-Woodhall and Hunter Woodhall, Olympic Power Couple
- Paul Fipps, President, Global Industries and Strategic Growth, ServiceNow
- Charles Davis, Director, Data & Analytics, Modern Niagara
- Shari Lava, Senior Director, AI and Automation, IDC
- Shawn Rogers, CEO, BARC US
- Matt Aslett, Director of Research, Analytics and Data, ISG Software Research
- Steve Lucas, Chairman and CEO, Boomi
- Ed Macosky, Chief Product and Technology Officer, Boomi
- Leaders from Infosys, Cognizant, and more!
Boomi World 2025 will feature an unparalleled lineup of keynote speakers and breakout sessions, giving attendees exclusive access to the insights and expertise of Boomi’s executive team, product leaders, customers, and partners. During the action-packed conference, attendees will explore the transformative power of agentic AI, get a peek behind the scenes at the Boomi product roadmap, and take a deep dive into real-world applications of API management (APIM), data management, integration, and automation.
Event Highlights:
| 1. | Special Guests Tara Davis-Woodhall and Hunter Woodhall
| |
| 2. | Exclusive Announcements Attendees will be the first to hear Boomi's latest product and platform updates, including product roadmap deep dives and planned strategic initiatives. Boomi World 2025 will feature exclusive announcements that will shape the future of AI, data management, API management, and integration and automation. | |
| 3. | Pre-Conference Training and Partner Summit
Starting on May 12, Boomi World will provide optional one and two-day Pre-Conference Training and certification courses, with in-depth sessions covering the various services within the Boomi Enterprise Platform, including integration, runtime architecture, API management, AI management, and data management.
| |
| 4. | 50+ Breakout Sessions Boomi World will offer more than 50 breakout sessions focused on AI, APIM, Data Management, and Integration: | |
AI (Artificial Intelligence) sessions cover the practical implementation and possibilities for enterprise AI, discussing Boomi AI Studio capabilities and running the gamut from orchestration and agentic AI to working with robots.
| ||
| 5. | Networking Opportunities Connect with technology thought-leaders, like-minded professionals, industry experts, and Boomi partners during dedicated networking sessions. Boomi World 2025 provides a unique platform to foster collaboration, share ideas, and build valuable relationships. |
Sponsors:
A special thanks to Boomi’s partner sponsors for helping make Boomi World 2025 possible, including ServiceNow as the Pinnacle sponsor, and Cognizant and Infosys as Diamond sponsors.
Registration:
Registration is open. Secure your spot at Boomi World 2025 by visiting BoomiWorld.com.
To join the Boomi World conversation on social media, use #BoomiWorld.
Additional Resources
- Follow Boomi on X (Twitter), LinkedIn, Facebook, and YouTube
About Boomi
Boomi, the intelligent integration and automation leader, helps organizations around the world automate and streamline critical processes to achieve business outcomes faster. Harnessing advanced AI capabilities, the Boomi Enterprise Platform seamlessly connects systems and manages data flows with API management, integration, data management, and AI orchestration in one comprehensive solution. With over 23,000 customers globally and a rapidly expanding network of 800+ partners, Boomi is revolutionizing the way enterprises of all sizes achieve business agility and operational excellence. Discover more at boomi.com.
© 2025 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250424969941/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release
Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize
Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release
Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom